-
The concept of RSV vaccine quietly heats up. Modena's "dilemma reversal" logic triggers a surge in loneliness
On the first trading day of the 2024 US stock market, just as the entire market was lackluster and plummeting, Moderna, a vaccine concept stock, pulled a big bullish line and was the only stock in th ... -
The approval of the 9-14 year old two dose vaccination program for the Merck East nine valent HPV vaccine will further expand the market size
On January 9th, MSD announced that its nine valent human papillomavirus vaccine (brewing yeast) (trade name: Jiada Xiu 9) has been approved by the National Medical Products Administration of China fo ... -
The approval of the 9-14 year old two dose vaccination program for the Merck East nine valent HPV vaccine will further expand the market size
On January 9th, MSD announced that its nine valent human papillomavirus vaccine (brewing yeast) (trade name: Jiada Xiu 9) has been approved by the National Medical Products Administration of China fo ... -
GSK's Vaccine Business Performs Strongly in 2023, with RSV Vaccine Revenue Exceeding $1.5 billion
On January 31st, GSK (GlaxoSmithKline) announced its 2023 results, with a full year revenue of 30.328 billion pounds (approximately 37.846 billion US dollars), a year-on-year increase of 5%; The oper ... -
Merck: Plan to conduct clinical trials of a new multivalent HPV vaccine
According to Merck, the company recently announced plans to launch a clinical trial of a novel multivalent human papillomavirus (HPV) vaccine aimed at providing broader protection against HPV types. ... -
AstraZeneca took the excuse of oversupply to remove COVID-19 vaccine globally and said that it had nothing to do with possible side effects
AstraZeneca, a British pharmaceutical company, said on May 7 that there has been a surplus of available vaccines since the outbreak of COVID-19, and the company has begun to remove NewCrown vaccines ... -
Sanofi infant syncytial virus nasal spray vaccine approved for clinical use in China
On May 31st, Sanofi announced that its infant nasal spray respiratory syncytial virus attenuated live vaccine (RSVt vaccine, SP0125) has been approved by the Drug Evaluation Center of the National Me ... -
Sanofi infant syncytial virus nasal spray vaccine approved for clinical use in China
On June 3rd, Southern Finance and Economics reported that Sanofi announced that its attenuated live vaccine for respiratory syncytial virus (RSVt vaccine, SP0125) for infants and young children has b ... -
Moderna's second mRNA vaccine has been approved for market launch. Aimei is launching a challenge with two heavyweight mRNA vaccine products
On June 4th, the leading domestic mRNA vaccine company Emmy Vaccine (06660. HK) announced that the company had submitted clinical trial pre applications for two heavyweight single products, the Respi ... -
Vaccine giant responds: nationwide suspension
Recently, the news of the suspension of the Pasteur flu vaccine under the vaccine giant Sanofi has attracted widespread market attention. On the afternoon of August 27th, a reporter from Shanghai Sec ... -
Interview with Li Weidong, Vice President of GSK and Head of China Vaccine Business: Promoting the deepening and consolidation of vaccine prescriptions, and deepening the integration of medical and prevention
21st Century Business Herald Ji Yuanyuan Intern Reporter Li Jiaying Reported from Shanghai The 7th China International Import Expo (referred to as "CIIE") was held as scheduled in Shanghai from Novem ... -
US vaccine stocks collectively fell! Trump appoints anti vaccine activist as US Secretary of Health
On Thursday, Trump announced his nomination of former independent presidential candidate Robert Kennedy Jr. as the Secretary of Health and Human Services in the new US government. For pharmaceutical ...